Education · Updated July 2026

503A vs 503B Compounding Pharmacies: What GLP-1 Patients Need to Know

The FDA's crackdown on compounded GLP-1 medications has made these two designations suddenly relevant for every patient seeking affordable semaglutide. Here's the difference — and why it matters for your access in 2026.

The Two Legal Pathways for Compounding

Compounding pharmacies in the United States operate under one of two sections of the Federal Food, Drug, and Cosmetic Act. These aren't just regulatory labels — they determine how the pharmacy operates, what it can produce, and how the FDA's recent enforcement actions affect its ability to compound GLP-1 medications.

Understanding which type of pharmacy fills your prescription helps you assess the legality, safety, and long-term reliability of your GLP-1 supply.

Section 503A: Patient-Specific Compounding

A 503A pharmacy is a traditional state-licensed compounding pharmacy. It operates under state oversight (not federal FDA registration) and compounds medications for individual patients based on specific prescriptions from licensed providers.

Key characteristics of 503A pharmacies: they fill prescriptions one patient at a time, they're regulated primarily by state boards of pharmacy, they compound using active ingredients from FDA-approved drug products or from the FDA's approved bulk substances list, and they do not produce large batches for general distribution.

For GLP-1 patients, 503A is the pathway that remains largely intact after the FDA's 2025-2026 regulatory actions. Because 503A compounding is based on individual prescriptions and doesn't depend on drug shortage list status, the FDA's removal of semaglutide from the shortage list didn't directly affect this pathway. Patients with valid prescriptions from licensed providers can still access compounded semaglutide through 503A pharmacies.

Section 503B: Outsourcing Facilities

A 503B pharmacy, also called an outsourcing facility, is voluntarily registered with the FDA and subject to federal current Good Manufacturing Practice (cGMP) inspections. These facilities can compound larger batches of medications, including without patient-specific prescriptions for "office use" by healthcare practitioners.

503B facilities were the primary source of mass-produced compounded semaglutide during the 2022-2024 shortage period. When demand exploded and brand-name supply couldn't keep up, these facilities scaled production to meet the gap.

This is the pathway the FDA has been aggressively restricting. When semaglutide and tirzepatide were removed from the drug shortage list in early 2025, 503B facilities lost the regulatory basis for producing "essentially a copy" of the branded drugs. The FDA's April 2026 proposal to formally exclude these drugs from the 503B Bulks List would permanently close this pathway, even if shortages returned.

Why This Matters for Your GLP-1 Access

If you're currently using or considering compounded semaglutide, knowing which type of pharmacy fills your prescription is directly relevant to the security of your supply. A 503A pharmacy operating under state oversight and filling individual prescriptions is on more stable regulatory ground than a 503B facility that may be subject to FDA enforcement actions.

Ask your telehealth provider which pharmacy compounds your medication and whether it operates under 503A or 503B. If it's a 503B facility, ask how the FDA's recent regulatory actions affect their ability to continue compounding GLP-1 medications. A transparent provider will answer these questions directly.

How to Verify a Compounding Pharmacy

For 503A pharmacies, check your state's board of pharmacy website. Every state maintains a searchable database of licensed pharmacies. Confirm the pharmacy holds a current, active license and is authorized for sterile compounding if you're receiving injectable medications.

For 503B outsourcing facilities, the FDA maintains a public list of registered facilities on its website. If a pharmacy claims to be a registered 503B facility, that claim should be verifiable through the FDA's database.

If you can't verify the pharmacy through either of these channels, treat that as a serious red flag. Legitimate compounding pharmacies are transparent about their licensing and registration because it's a competitive advantage — not something to hide.

This article is for informational purposes only and does not constitute medical or legal advice. Regulatory status of compounded GLP-1 medications is subject to change. Consult a licensed healthcare provider before starting any medication. Information current as of July 2026.